News >

FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jan 15, 2019

Jane Huang, MD

Jane Huang, MD
The FDA has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least 1 prior therapy, according to BeiGene, the company manufacturing the agent.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication